Updated:
Hikma Ventures
Hikma Ventures was founded in 2015 by Hikma Pharmaceuticals as the group's dedicated corporate venture capital arm.
Hikma Ventures
Hikma Ventures was founded in 2015 by Hikma Pharmaceuticals as the group's dedicated corporate venture capital arm. Based in London, the unit is led by Managing Director Lana Ghanem. The vehicle draws its capital from Hikma Pharmaceuticals, a FTSE 100 generics and branded medicines maker with deep manufacturing and distribution roots across the Middle East, North Africa, and the US — giving the venture arm a balance-sheet anchor rather than a third-party LP base. Strategy centers on early-stage to growth investments in digital health, enterprise software, and AI/ML. The team targets Seed through Series B rounds, writing checks sized for meaningful minority stakes. The mandate favors startups that can align with Hikma's pharmaceutical infrastructure — supply-chain tech, clinical workflow platforms, and AI-driven diagnostics. Confirmed portfolio names include Ovation, a US-based lab-agnostic genetic testing marketplace, and Prognos, a clinical analytics platform applying AI to lab data. Total deployment capacity is $250 million, drawn directly from the corporate parent, making it one of the few purely corporate VC setups with multi-hundred-million-dollar firepower in European health tech. Its investment footprint stretches across North America and EMEA — the two regions where Hikma operates physical manufacturing and distribution. In January 2025, the firm continued its active pacing with a follow-on into a portfolio company's bridge round, consistent with its hands-on corporate VC posture. A structural differentiator for Hikma Ventures is the bidirectional channel to Hikma Pharmaceuticals' operating business — portfolio companies can navigate FDA manufacturing standards, Middle Eastern regulatory pathways, and US generics distribution through a single corporate parent, while Hikma captures an early view of technologies that may reshape its core markets.
General information
Firm type
Venture Capital
Year founded
2015
AUM
$100M–$500M (Altss estimate)
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Lana Ghanem
Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at Hikma Ventures?
Lana Ghanem serves as Managing Director and leads the investment team from London. She oversees deal sourcing, execution, and portfolio management, reporting into the broader Hikma Pharmaceuticals corporate structure. Investment committee processes typically involve coordination with senior pharmaceutical-side executives given the corporate VC model.
How does Hikma Ventures source proprietary deal flow?
Hikma Ventures leans heavily on Hikma Pharmaceuticals' operating footprint in North America and the Middle East for sourcing. The team gains early looks at health-tech startups through the parent's relationships with hospital systems, generics buyers, and regulatory bodies. The firm also participates in traditional VC networks across London and Silicon Valley for enterprise software and AI exposure.
Does Hikma Ventures participate in fund commitments or only direct deals?
The firm primarily executes direct deals, taking minority equity positions in Seed through Series B rounds. There is no public indication of a fund-of-funds program. The capital is drawn directly from Hikma Pharmaceuticals' balance sheet, so structures tend toward direct minority investments rather than LP commitments to outside managers.
What investment stages does Hikma Ventures typically target?
Seed, Series A, and Series B rounds form the core stage mandate. The firm occasionally participates in later growth rounds for portfolio companies, but its stated focus is early-stage to growth-stage, aligning with corporate venture capital norms where early engagement maximizes both financial return potential and strategic insight for the parent.
How is Hikma Ventures related to Hikma Pharmaceuticals?
Hikma Ventures is wholly owned and funded by Hikma Pharmaceuticals, the London-listed, FTSE 100 generics and branded medicines company. It functions as the corporate venture capital division, with its $250 million investment capacity coming directly from the parent's treasury function rather than from external limited partners.
Where does Hikma Ventures deploy geographically?
The firm invests primarily in North America and EMEA, mirroring Hikma Pharmaceuticals' operational base. The US and UK are both active hunting grounds, with the Middle East emerging as a region of interest aligned with the parent's expanding manufacturing footprint there.
Which sectors does Hikma Ventures explicitly avoid?
Hikma Ventures does not publicly maintain an exclusion list, but its mandate is tightly drawn around digital health, enterprise software, and AI/ML — sectors directly relevant to Hikma Pharmaceuticals' manufacturing, distribution, and clinical workflows. Deep-tech hardware, consumer apps, and therapeutics development fall outside its observed investment pattern.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: